Cardiff Oncology (CRDF) Expected to Announce Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cardiff Oncology to post earnings of ($0.18) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Cardiff Oncology Price Performance

CRDF opened at $1.56 on Thursday. The firm’s fifty day moving average price is $2.42 and its two-hundred day moving average price is $2.28. The company has a market capitalization of $105.08 million, a P/E ratio of -1.97 and a beta of 1.33. Cardiff Oncology has a fifty-two week low of $1.48 and a fifty-two week high of $4.99.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CRDF. Noble Financial assumed coverage on Cardiff Oncology in a report on Monday, January 5th. They set an “outperform” rating and a $12.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.13.

Hedge Funds Weigh In On Cardiff Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRDF. Brooklyn Investment Group acquired a new stake in shares of Cardiff Oncology in the 3rd quarter valued at approximately $26,000. Engineers Gate Manager LP bought a new stake in Cardiff Oncology in the second quarter valued at approximately $43,000. BNP Paribas Financial Markets raised its holdings in Cardiff Oncology by 335.1% in the second quarter. BNP Paribas Financial Markets now owns 15,437 shares of the company’s stock worth $49,000 after purchasing an additional 11,889 shares during the period. Raymond James Financial Inc. boosted its position in shares of Cardiff Oncology by 70.1% during the third quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock worth $49,000 after purchasing an additional 9,740 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Cardiff Oncology by 23.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock valued at $69,000 after buying an additional 4,232 shares during the period. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.